May 2003
Volume 44, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2003
Adverse Effects of Topical Latanoprost on Experimental Autoimmune Uveitis
Author Affiliations & Notes
  • T. Kaburaki
    Department of Ophthalmology, The Univ of Tokyo School of Medicine, Bunkyo-Ku, Japan
  • A. Yoshida
    Department of Ophthalmology, The Univ of Tokyo School of Medicine, Bunkyo-Ku, Japan
  • S. Fujimura
    Department of Ophthalmology, The Univ of Tokyo School of Medicine, Bunkyo-Ku, Japan
  • K. Akiyama
    Department of Ophthalmology, The Univ of Tokyo School of Medicine, Bunkyo-Ku, Japan
  • J. Numaga
    Department of Ophthalmology, The Univ of Tokyo School of Medicine, Bunkyo-Ku, Japan
  • Y. Fujino
    Department of Ophthalmology, The Univ of Tokyo School of Medicine, Bunkyo-Ku, Japan
  • H. Kawashima
    Department of Ophthalmology, The Univ of Tokyo School of Medicine, Bunkyo-Ku, Japan
  • Footnotes
    Commercial Relationships  T. Kaburaki, None; A. Yoshida, None; S. Fujimura, None; K. Akiyama, None; J. Numaga, None; Y. Fujino, None; H. Kawashima, None.
Investigative Ophthalmology & Visual Science May 2003, Vol.44, 723. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Kaburaki, A. Yoshida, S. Fujimura, K. Akiyama, J. Numaga, Y. Fujino, H. Kawashima; Adverse Effects of Topical Latanoprost on Experimental Autoimmune Uveitis . Invest. Ophthalmol. Vis. Sci. 2003;44(13):723.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Because of the controversy surrounding possible adverse side effects as a result of topical latanoprost (Lat), anti-glaucoma eyedrop of prostaglandin F2a analog, usage on patients with uveitis, we examined the influence of topical Lat on the severity of experimental autoimmune uveitis (EAU) in rats. Methods: EAU was induced with 50µg of S-Ag peptide in Lewis rats. Sixty rats were divided into four groups (Group1: benzalkonium chloride (vehicle) only, Group2: Lat, Group3: Dexamethazone (DEX)+vehicle, Group4: DEX+Lat, each n=15). 10µl of eyedrop was applied each time. Dex was applied twice a day, Lat and vehicle were applied once a day. The onset and severity of EAU were monitored with a slit lamp everyday and evaluated by the combined EAU score (0-4 in each eye) of both eyes. Results: The average days of the onsets of EAU were 9.8±0.9, 10.4±1.1, 16.3±3.9, and 14.7±2.2 in Groups 1-4, respectively. The peak of EAU was observed on day 12, 12, 16, and 17, respectively . The peak values of the EAU score were 7.1±0.2, 6.1±0.6, 3.0±0.8, and 3.3±0.7 (average ± standard error ), respectively. There were no significant differences of the onset day and the peak values of EAU score in Group 1 vs Group 2, and in Group 3 vs Group 4. Conclusions: Obvious adverse side effects of topical latanoprost on EAU were not detected clinically in this study. Pathological examinations are currently in progress to further elucidate the issue.

Keywords: uveitis-clinical/animal model • pharmacology • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×